Effects of the CYP3A inhibitors, voriconazole, itraconazole, and fluconazole on the pharmacokinetics of osimertinib in rats
Authors:
Open Access
Abstract
Background: Osimertinib, as third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is the first-line treatment approved to treat advanced T790M mutation-positive tumors. Triazole antifungals are therapeutic drugs for cancer patients to reduce the risk of opportunistic fungal infections. Our objective was to investigate whether three triazole antifungals (voriconazole, itraconazole, and fluconazole) could change the pharmacokinetics of osimertinib in rats. Methods: The adult male Sprague-Dawley rats were randomly divided into four groups (n = 6): control (0.3% CMC-Na), and voriconazole (20 mg/kg), itraconazole (20 mg/kg), or fluconazole (20 mg/kg) combined with osimertinib (10 mg/kg) group. Tail vein blood samples were collected into heparin tubes at various time points within 0–48 h after osimertinib administration. Osimrtinib’s plasma concentration was detected using HPLC-MS/MS system equipped with a Waters XBridge C18 column, with the mobile phase consisting of acetonitrile and 0.2% formic acid water at a flow rate of 0.5 mL/min. Results: Co-administration with voriconazole or fluconazole increased the Cmax of osimertinib by 58.04% and 53.45%, respectively; the AUC0–t increased by 62.56% and 100.98%, respectively. However, when co-administered with itraconazole, the Cmax and AUC0–t of osimertinib only increased by 13.91% and 34.80%, respectively. Conclusions: Our results revealed that the pharmacokinetics of osimertinib were significantly changed by voriconazole and fluconazole in rats, whereas it was slightly affected by itraconazole. This work will contribute to a more comprehensive understanding of the pharmacokinetic properties of osimertinib when co-administered with triazole antifungals.Keywords
Funding Information
- Zhejiang Provincial Natural Science Foundation of China (LYQ20H310001, LYY21H310011)
- Chinese Medicine Research Program of Zhejiang Province (2021ZZ001)
- Medical and Health Research Program of Zhejiang Province (2021KY040, 2022KY069)
This publication has 36 references indexed in Scilit:
- Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2018
- Pharmacokinetic Drug Interactions of Apatinib With Rifampin and ItraconazoleThe Journal of Clinical Pharmacology, 2017
- Population pharmacokinetics and exposure‐response of osimertinib in patients with non‐small cell lung cancerBritish Journal of Clinical Pharmacology, 2017
- Best practices for the use of itraconazole as a replacement for ketoconazole in drug–drug interaction studiesThe Journal of Clinical Pharmacology, 2015
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug–drug interactionsCancer Treatment Reviews, 2014
- Mining clinical text for signals of adverse drug-drug interactionsJournal of the American Medical Informatics Association, 2014
- Simultaneous and comprehensivein vivoanalysis of cytochrome P450 activity by using a cocktail approach in ratsBiopharmaceutics & Drug Disposition, 2014
- Evaluation of the Practice of Antifungal Prophylaxis Use in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results From the SEIFEM 2010-B RegistryClinical Infectious Diseases, 2012
- The Enzymatic Basis of Drug-Drug Interactions with Systemic Triazole AntifungalsClinical Pharmacokinetics, 2008